Sec. 1372.001.  DEFINITIONS.  In this chapter:
(1)  "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. The term includes:
(A)  gene mutations; and
(B)  protein expression.
(2)  "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker.  The term includes:
(A)  single-analyte tests;
(B)  multiplex panel tests; and
(C)  whole genome sequencing.
(3)  "Consensus statements" means statements that:
(A)  address specific clinical circumstances based on the best available evidence for the purpose of optimizing clinical care outcomes; and
(B)  are developed by an independent, multidisciplinary panel of experts that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy.
(4)  "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that:
(A)  establish a standard of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options;
(B)  include recommendations intended to optimize patient care; and
(C)  are developed by an independent organization or medical professional society that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy.
Added by Acts 2023, 88th Leg., R.S., Ch. 279 (S.B. 989), Sec. 1, eff. September 1, 2023.